Oxaliplatin pharmacokinetics during a four-hour infusion

Citation
W. Kern et al., Oxaliplatin pharmacokinetics during a four-hour infusion, CLIN CANC R, 5(4), 1999, pp. 761-765
Citations number
52
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
10780432 → ACNP
Volume
5
Issue
4
Year of publication
1999
Pages
761 - 765
Database
ISI
SICI code
1078-0432(199904)5:4<761:OPDAFI>2.0.ZU;2-C
Abstract
A new platin compound, oxaliplatin, has significant activity in advanced co lorectal carcinomas. However, its pharmacokinetics have not been characteri zed adequately yet. This study extensively analyzes the pharmacokinetics of both ultrafiltrable (free) and protein-bound platin in 13 patients receivi ng 130 mg/m(2) oxaliplatin as a 4-h infusion in combination with 375 mg/m(2 ) 5-fluorouracil as a 24-h infusion for advanced colorectal carcinomas. The interpatient variability was very low for all parameters analyzed. The lev els of free platin decreased triphasically, with a mean terminal half-life of 27.3 +/- 10.6 h. The area under the time-concentration curve was 20.17 /- 6.97 mu g.h/ml and the total and renal clearances amounted to 222 +/- 65 and 121 +/- 56 ml/min, respectively. The values for the volume of distribu tion and for the maximum concentration at the end of infusion were 349 +/- 132 liters and 1612 +/- 553 ng/ml, respectively. On the basis of the simula tion of the plasma levels and the urinary excretion of platin following the long-term administration of oxaliplatin as a constant-rate and a chronomod ulated infusion, additional analyses are warranted to fully characterize th e pharmacokinetics of the drug in these settings.